Status: Recruiting
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Participants needed: 422
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Personalis Inc.Updated: Jan 7, 2025Locations: 14
Eligibility criteria
Have histologically documented TNBC (defined as ER expression ≤10% by IHC, PR ex... [+7]
Receiving concurrent anti-neoplastic therapy for another malignancy. [+6]